Respiratory medicine case reports · 2025
Metastatic lung pleomorphic giant cell carcinoma treated with multimodality systemic anti-cancer treatment, a two-year journey: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kanbour Aladdin, Alnajjar Afnan, AbuHaweeleh Mohannad N, Al-Bozom Issam, Wazwaz Bara, Haroon Athar, Madhar Razhan, Saman Harman
Аннотация
INTRODUCTION: Pleomorphic giant cell carcinoma (PGCC) of the lung is a rare and aggressive subtype of non-small cell lung cancer with limited therapeutic options. We present a case of a 50-year-old male with stage IV, PD-L1-negative PGCC managed through a sequential multimodal treatment approach.
CASE PRESENTATION: A 50 year old gentleman, known to be a heavy smoker, presented with metastatic disease involving the lungs, bone, and lymph nodes. He received dual immunotherapy with Nivolumab and Ipilimumab, achieving a partial response before progression. Subsequent MAID chemotherapy provided transient disease control, followed by Carboplatin-Paclitaxel, which yielded a more durable response. With additional radiotherapy for brain metastases, the patient achieved an overall survival of 30 months.
CONCLUSION: This case underscores the rarity and therapeutic complexity of metastatic PGCC and highlights the potential survival benefit of an adaptive, multidisciplinary treatment strategy integrating immunotherapy, chemotherapy, and targeted radiotherapy.
CASE PRESENTATION: A 50 year old gentleman, known to be a heavy smoker, presented with metastatic disease involving the lungs, bone, and lymph nodes. He received dual immunotherapy with Nivolumab and Ipilimumab, achieving a partial response before progression. Subsequent MAID chemotherapy provided transient disease control, followed by Carboplatin-Paclitaxel, which yielded a more durable response. With additional radiotherapy for brain metastases, the patient achieved an overall survival of 30 months.
CONCLUSION: This case underscores the rarity and therapeutic complexity of metastatic PGCC and highlights the potential survival benefit of an adaptive, multidisciplinary treatment strategy integrating immunotherapy, chemotherapy, and targeted radiotherapy.